These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27924779)

  • 1. Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Rockstroh JK; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Zhang-Roper R; Wang R; Pineda JA; Heera J
    Antivir Ther; 2017; 22(3):263-269. PubMed ID: 27924779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.
    Rockstroh JK; Soriano V; Plonski F; Bansal M; Fätkenheuer G; Small CB; Asmuth DM; Pialoux G; Mukwaya G; Jagannatha S; Heera J; Pineda JA
    HIV Clin Trials; 2015; 16(2):72-80. PubMed ID: 25923596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
    Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
    HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
    Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
    N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
    Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
    Perry CM
    Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
    Gulick RM; Wilkin TJ; Chen YQ; Landovitz RJ; Amico KR; Young AM; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; McGowan I; Cottle LM; Andrade A; Marcus C; Klingman KL; Chege W; Rinehart AR; Rooney JF; Andrew P; Salata RA; Siegel M; Manabe YC; Frank I; Ho K; Santana J; Stekler JD; Swaminathan S; McCauley M; Hodder S; Mayer KH
    Ann Intern Med; 2017 Sep; 167(6):384-393. PubMed ID: 28828489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.
    Gulick RM; Fatkenheuer G; Burnside R; Hardy WD; Nelson MR; Goodrich J; Mukwaya G; Portsmouth S; Heera JR
    J Acquir Immune Defic Syndr; 2014 Jan; 65(1):78-81. PubMed ID: 24419064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
    Crespo M; Navarro J; Moreno S; Sanz J; Márquez M; Zamora J; Ocampo A; Iribaren JA; Rivero A; Llibre JM
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):493-498. PubMed ID: 27061975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
    van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
    PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice.
    Genebat M; Ruiz-Mateos E; Pulido I; González-Serna A; García-Pergañeda A; Méndez G; Romero-Sánchez MC; Ferrando-Martínez S; Leal M
    Curr HIV Res; 2010 Sep; 8(6):482-6. PubMed ID: 20642436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
    J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection: A Randomized Trial.
    Lévy Y; Lelièvre JD; Assoumou L; Aznar E; Pulido F; Tambussi G; Crespo M; Meybeck A; Molina JM; Delaugerre C; Izopet J; Peytavin G; Cardon F; Diallo A; Lancar R; Béniguel L; Costagliola D
    Ann Intern Med; 2020 Mar; 172(5):297-305. PubMed ID: 32040959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.